Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice.

Chen D, Li K, Tham EL, Wei LL, Ma N, Dodd PC, Luo Y, Kirchhofer D, McVey JH, Dorling A.

Front Immunol. 2018 Jul 2;9:1517. doi: 10.3389/fimmu.2018.01517. eCollection 2018.

2.

Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.

Manook M, Kwun J, Sacks S, Dorling A, Mamode N, Knechtle S.

Transplant Rev (Orlando). 2018 Jul;32(3):119-126. doi: 10.1016/j.trre.2018.01.001. Epub 2018 Feb 10. Review.

PMID:
29935708
3.

Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies.

Kim JJ, Shaw O, Martin C, Michaelides G, Balasubramaniam R, Sebire NJ, Mamode N, Dorling A, Vaughan R, Marks SD.

Pediatr Nephrol. 2018 Jan;33(1):167-174. doi: 10.1007/s00467-017-3772-7. Epub 2017 Sep 16.

4.

Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation.

Manook M, Kwun J, Burghuber C, Samy K, Mulvihill M, Yoon J, Xu H, MacDonald AL, Freischlag K, Curfman V, Branum E, Howell D, Farris AB, Smith RA, Sacks S, Dorling A, Mamode N, Knechtle SJ.

Am J Transplant. 2017 Aug;17(8):2055-2064. doi: 10.1111/ajt.14234. Epub 2017 Mar 23. Erratum in: Am J Transplant. 2017 Nov;17 (11):2993.

PMID:
28226413
5.

Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis.

Manook M, Koeser L, Ahmed Z, Robb M, Johnson R, Shaw O, Kessaris N, Dorling A, Mamode N.

Lancet. 2017 Feb 18;389(10070):727-734. doi: 10.1016/S0140-6736(16)31595-1. Epub 2017 Jan 6. Erratum in: Lancet. 2017 Feb 18;389(10070):700.

PMID:
28065559
6.

Transitional B cell subsets-a convincing predictive biomarker for allograft loss?

Burton H, Dorling A.

Kidney Int. 2017 Jan;91(1):18-20. doi: 10.1016/j.kint.2016.10.028.

PMID:
28003081
7.

Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.

Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Burton H, Douthwaite H, Wilkinson H, Semik V, Dodd PC, Brookes P, Lechler RI, Hernandez-Fuentes MP, Kemper C, Dorling A.

Kidney Int. 2017 Feb;91(2):477-492. doi: 10.1016/j.kint.2016.10.009. Epub 2016 Dec 15.

8.

Organ Pretreatment With Cytotopic Endothelial Localizing Peptides to Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal Hemoreperfusion Models.

Hamaoui K, Gowers S, Boutelle M, Cook TH, Hanna G, Darzi A, Smith R, Dorling A, Papalois V.

Transplantation. 2016 Dec;100(12):e128-e139.

PMID:
27861293
9.

Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation.

Karegli J, Melchionna T, Farrar CA, Greenlaw R, Smolarek D, Horsfield C, Charif R, McVey JH, Dorling A, Sacks SH, Smith RA.

Am J Transplant. 2017 Jan;17(1):272-280. doi: 10.1111/ajt.13951. Epub 2016 Aug 8.

10.

Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial.

Karunanithy N, Mesa IR, Dorling A, Calder F, Katsanos K, Semik V, Robinson E, Peacock J, Das N, Forman C, Lawman S, Steiner K, Wilkins CJ, Robson MG.

Trials. 2016 May 12;17(1):241. doi: 10.1186/s13063-016-1372-7.

11.

APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.

Xiao F, Ma L, Zhao M, Smith RA, Huang G, Jones PM, Persaud S, Pingitore A, Dorling A, Lechler R, Lombardi G.

Br J Pharmacol. 2016 Feb;173(3):575-87. doi: 10.1111/bph.13388. Epub 2016 Jan 11.

12.

Incidence and Outcome of C4d Staining With Tubulointerstitial Inflammation in Blood Group-incompatible Kidney Transplantation.

Couzi L, Perera R, Manook M, Barnett AN, Shaw O, Kessaris N, Marks SD, Dorling A, Mamode N.

Transplantation. 2015 Jul;99(7):1487-94. doi: 10.1097/TP.0000000000000556.

PMID:
26151608
13.

Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations.

Couzi L, Manook M, Perera R, Shaw O, Ahmed Z, Kessaris N, Dorling A, Mamode N.

Transpl Int. 2015 Oct;28(10):1205-15. doi: 10.1111/tri.12621. Epub 2015 Jul 6.

14.

B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.

Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Semik V, Cook HT, Roufosse C, Brookes P, Bowers RW, Galliford J, Taube D, Lechler RI, Hernandez-Fuentes MP, Dorling A.

Kidney Int. 2015 Sep;88(3):560-8. doi: 10.1038/ki.2015.100. Epub 2015 Apr 1.

PMID:
25830760
15.

Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE-/- mice.

Chen D, Xia M, Hayford C, Tham el-L, Semik V, Hurst S, Chen Y, Tam HH, Pan J, Wang Y, Tan X, Lan HY, Shen H, Kakkar VV, Xu Q, McVey JH, Dorling A.

Circulation. 2015 Apr 14;131(15):1350-60. doi: 10.1161/CIRCULATIONAHA.114.013423. Epub 2015 Feb 12.

16.

Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.

Tsai MC, Chen KD, Wang CC, Huang KT, Wu CH, Kuo IY, Chen LY, Hu TH, Goto S, Nakano T, Dorling A, McVey JH, Chen CL, Lin CC.

Cell Death Discov. 2015 Nov 30;1:15051. doi: 10.1038/cddiscovery.2015.51. eCollection 2015.

17.

Optimising long-term graft survival: establishing the benefit of targeting B lymphocytes.

Shiu KY, Dorling A.

Clin Med (Lond). 2014 Dec;14 Suppl 6:s84-8. doi: 10.7861/clinmedicine.14-6-s84. Review.

PMID:
25468927
18.
19.

Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rγnull mice.

Xiao F, Ma L, Zhao M, Huang G, Mirenda V, Dorling A, Lechler R, Lombardi G.

PLoS One. 2014 Mar 3;9(3):e90387. doi: 10.1371/journal.pone.0090387. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98722.

20.

Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial.

Dorling A, Rebollo-Mesa I, Hilton R, Peacock JL, Vaughan R, Gardner L, Danzi G, Baker R, Clark B, Thuraisingham RC, Buckland M, Picton M, Martin S, Borrows R, Briggs D, Horne R, McCrone P, Kelly J, Murphy C.

Trials. 2014 Jan 21;15:30. doi: 10.1186/1745-6215-15-30.

21.

Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.

Barnett AN, Manook M, Nagendran M, Kenchayikoppad S, Vaughan R, Dorling A, Hadjianastassiou VG, Mamode N.

Transpl Int. 2014 Feb;27(2):187-96. doi: 10.1111/tri.12234. Epub 2013 Dec 28.

22.

Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.

Chen D, McVey JH, Dorling A.

Thromb Res. 2013;132(6):750-6. doi: 10.1016/j.thromres.2013.10.002. Epub 2013 Oct 11.

PMID:
24161661
23.

Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms.

Chen D, Ma L, Tham EL, Maresh S, Lechler RI, McVey JH, Dorling A.

J Thromb Haemost. 2013 May;11(5):963-74. doi: 10.1111/jth.12198.

24.

The use of eculizumab in renal transplantation.

Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N.

Clin Transplant. 2013 May-Jun;27(3):E216-29. doi: 10.1111/ctr.12102. Epub 2013 Mar 21. Review.

PMID:
23516966
25.

Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.

Shrivastava S, Ma L, Tham el-L, H McVey J, Chen D, Dorling A.

Immunology. 2013 Jun;139(2):219-26. doi: 10.1111/imm.12073.

26.

A new and clinically relevant murine model of solid-organ transplant aspergillosis.

Herbst S, Shah A, Carby M, Chusney G, Kikkeri N, Dorling A, Bignell E, Shaunak S, Armstrong-James D.

Dis Model Mech. 2013 May;6(3):643-51. doi: 10.1242/dmm.010330. Epub 2012 Dec 20.

27.

Renal allograft recipients fail to increase interferon-γ during invasive fungal diseases.

Armstrong-James D, Teo I, Herbst S, Petrou M, Shiu KY, McLean A, Taube D, Dorling A, Shaunak S.

Am J Transplant. 2012 Dec;12(12):3437-40. doi: 10.1111/j.1600-6143.2012.04254.x. Epub 2012 Sep 13.

28.

Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.

Ekser B, Lin CC, Long C, Echeverri GJ, Hara H, Ezzelarab M, Bogdanov VY, Stolz DB, Enjyoji K, Robson SC, Ayares D, Dorling A, Cooper DK, Gridelli B.

Transpl Int. 2012 Aug;25(8):882-96. doi: 10.1111/j.1432-2277.2012.01506.x. Epub 2012 May 30.

29.

Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation?

Dorling A.

Am J Transplant. 2012 Mar;12(3):545-53. doi: 10.1111/j.1600-6143.2011.03821.x. Epub 2011 Nov 2. Review.

30.

Inhibition of thrombin receptor signaling on α-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury.

Chen D, Shrivastava S, Ma L, Tham el-L, Abrahams J, Coe JD, Scott D, Lechler RI, McVey JH, Dorling A.

Arterioscler Thromb Vasc Biol. 2012 Jan;32(1):42-9. doi: 10.1161/ATVBAHA.111.239046. Epub 2011 Oct 27.

31.

Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.

Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe M, McLean AG.

Transplantation. 2011 Oct 15;92(7):774-80. doi: 10.1097/TP.0b013e31822ca7ca.

PMID:
21836540
32.

The roles of thrombin and protease-activated receptors in inflammation.

Ma L, Dorling A.

Semin Immunopathol. 2012 Jan;34(1):63-72. doi: 10.1007/s00281-011-0281-9. Epub 2011 Aug 2. Review.

PMID:
21809138
33.

Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome.

Willicombe M, Roufosse C, Brookes P, Galliford JW, McLean AG, Dorling A, Warrens AN, Cook TH, Cairns TD, Taube D.

Transplantation. 2011 Jul 27;92(2):176-82. doi: 10.1097/TP.0b013e318222c9c6.

PMID:
21637139
34.

Pancreatic-derived pathfinder cells enable regeneration of critically damaged adult pancreatic tissue and completely reverse streptozotocin-induced diabetes.

Stevenson K, Chen D, MacIntyre A, McGlynn LM, Montague P, Charif R, Subramaniam M, George WD, Payne AP, Davies RW, Dorling A, Shiels PG.

Rejuvenation Res. 2011 Apr;14(2):163-71. doi: 10.1089/rej.2010.1099. Epub 2011 Mar 19.

PMID:
21417783
35.

Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy.

Willicombe M, Brookes P, Santos-Nunez E, Galliford J, Ballow A, Mclean A, Roufosse C, Cook HT, Dorling A, Warrens AN, Cairns T, Taube D.

Am J Transplant. 2011 Mar;11(3):470-7. doi: 10.1111/j.1600-6143.2010.03421.x. Epub 2011 Feb 7.

36.

Plasmapheresis as rescue therapy for systemic lupus erthyematosus-associated diffuse alveolar haemorrhage.

Claridge S, Das P, Dorling A, Robson MG.

BMJ Case Rep. 2011 Mar 15;2011. pii: bcr0220113893. doi: 10.1136/bcr.02.2011.3893. Erratum in: BMJ Case Rep. 2012;2012. doi:10.1136/bcr.02.2011.3893.corr1. Robson, Michael [corrected to Robson, Michael G].

37.

B cells in renal transplantation: pathological aspects and therapeutic interventions.

Barnett N, Dorling A, Mamode N.

Nephrol Dial Transplant. 2011 Mar;26(3):767-74. doi: 10.1093/ndt/gfq716. Epub 2010 Dec 7. Review.

PMID:
21139038
38.

Rituximab may not lead to increased infection rates in transplant recipients.

Drage M, Hadjianastassiou V, Dorling A, Mamode N.

Am J Transplant. 2010 Dec;10(12):2723-4. doi: 10.1111/j.1600-6143.2010.03195.x. No abstract available.

39.

Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation.

Lin CC, Ezzelarab M, Shapiro R, Ekser B, Long C, Hara H, Echeverri G, Torres C, Watanabe H, Ayares D, Dorling A, Cooper DK.

Am J Transplant. 2010 Jul;10(7):1556-68. doi: 10.1111/j.1600-6143.2010.03147.x.

40.

Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells.

Lin CC, Ezzelarab M, Hara H, Long C, Lin CW, Dorling A, Cooper DK.

J Thromb Haemost. 2010 Sep;8(9):2001-10. doi: 10.1111/j.1538-7836.2010.03950.x.

41.

Smooth muscle cells in porcine vein graft intimal hyperplasia are derived from the local vessel wall.

Jevon M, Ansari TI, Finch J, Zakkar M, Evans PC, Shurey S, Sibbons PD, Hornick P, Haskard DO, Dorling A.

Cardiovasc Pathol. 2011 May-Jun;20(3):e91-4. doi: 10.1016/j.carpath.2010.04.003. Epub 2010 Jun 7.

PMID:
20537564
42.

Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients.

Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, Dorling A, Shaunak S.

Am J Transplant. 2010 Aug;10(8):1796-803. doi: 10.1111/j.1600-6143.2010.03094.x. Epub 2010 Mar 26.

43.

An ex-vivo model for hypothermic pulsatile perfusion of porcine pancreata: hemodynamic and morphologic characteristics.

Karcz M, Cook HT, Sibbons P, Gray C, Dorling A, Papalois V.

Exp Clin Transplant. 2010 Mar;8(1):55-60.

44.

Current status of xenotransplantation and prospects for clinical application.

Pierson RN 3rd, Dorling A, Ayares D, Rees MA, Seebach JD, Fishman JA, Hering BJ, Cooper DK.

Xenotransplantation. 2009 Sep-Oct;16(5):263-80. doi: 10.1111/j.1399-3089.2009.00534.x. Review.

45.

Donor HO-1 expression inhibits intimal hyperplasia in unmanipulated graft recipients: a potential role for CD8+ T-cell modulation by carbon monoxide.

Clarke HM, Shrivastava S, Motterlini R, Sawle P, Chen D, Dorling A.

Transplantation. 2009 Sep 15;88(5):653-61. doi: 10.1097/TP.0b013e3181b2fd83.

PMID:
19741462
46.

Critical roles for thrombin in acute and chronic inflammation.

Chen D, Dorling A.

J Thromb Haemost. 2009 Jul;7 Suppl 1:122-6. doi: 10.1111/j.1538-7836.2009.03413.x. Review.

47.

Regulation of rat and human T-cell immune response by pharmacologically modified dendritic cells.

Fazekasova H, Golshayan D, Read J, Tsallios A, Tsang JY, Dorling A, George AJ, Lechler RI, Lombardi G, Mirenda V.

Transplantation. 2009 Jun 15;87(11):1617-28. doi: 10.1097/TP.0b013e3181a5504c.

PMID:
19502952
48.

Coagulation dysregulation as a barrier to xenotransplantation in the primate.

Lin CC, Cooper DK, Dorling A.

Transpl Immunol. 2009 Jun;21(2):75-80. doi: 10.1016/j.trim.2008.10.008. Epub 2008 Nov 10. Review.

49.

ABO incompatible living renal transplantation with a steroid sparing protocol.

Galliford J, Charif R, Chan KK, Loucaidou M, Cairns T, Cook HT, Dorling A, Hakim N, McLean A, Papalois V, Malde R, Regan F, Redman M, Warrens AN, Taube D.

Transplantation. 2008 Oct 15;86(7):901-6. doi: 10.1097/TP.0b013e3181880c0f.

PMID:
18852653
50.

Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells.

Lin CC, Chen D, McVey JH, Cooper DK, Dorling A.

Transplantation. 2008 Sep 15;86(5):702-9. doi: 10.1097/TP.0b013e31818410a3.

Supplemental Content

Loading ...
Support Center